Home › Funds › Birchview Capital, LP › PHVS
Birchview Capital, LP position in PHVS
PHARVARIS N V · Health Care
Birchview Capital, LP reported holding 29,847 shares of PHVS (PHARVARIS N V) in its Q3 2026 13F filing — a position valued at US$947K, representing 0.56% of its reported portfolio and ranking #40 among its reported holdings. Birchview Capital, LP has disclosed PHVS holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Birchview Capital, LP's PHVS position evolved
Birchview Capital, LP first disclosed a stake in PHVS in Q3 2025 at 14,847 shares (US$370K). The position peaked in Q2 2026 at 29,847 shares, worth US$1.0M. Across 5 filings, Birchview Capital, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 29,847 shares valued at US$947K. Notable position changes include a 101% increase in Q4 2025 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 14.85K | $370.43K | New |
| Q4 2025 | 29.85K | $828.25K | Add |
| Q1 2026 | 29.85K | $843.18K | Hold |
| Q2 2026 | 29.85K | $1.03M | Hold |
| Q3 2026 | 29.85K | $946.75K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHVS and 13F data
PHVS (PHARVARIS N V) is a Health Care company. 51 other funds we track also report a position in PHVS — the largest reported positions include Foresite Capital Management IV, LLC (US$165.2M), venBio Partners LLC (US$160.6M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$116.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHVS
- Foresite Capital Management IV, LLC 4.78M sh · $165.24M · Q2 2026
- venBio Partners LLC 4.64M sh · $160.57M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.38M sh · $116.74M · Q2 2026
- EQT Fund Management S.a r.l. 3.42M sh · $108.63M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 2.68M sh · $92.52M · Q2 2026
- GENERAL ATLANTIC, L.P. 1.65M sh · $52.39M · Q3 2026
- Commodore Capital LP 1.43M sh · $49.28M · Q2 2026
- Novo Holdings A/S 1.40M sh · $48.41M · Q2 2026
- Saturn V Capital Management LP 1.31M sh · $45.44M · Q2 2026
- TCG Crossover Management, LLC 1.01M sh · $34.86M · Q2 2026
- Jones Hill Capital LP 987.64K sh · $31.33M · Q3 2026
- Sofinnova Investments, Inc. 881.30K sh · $30.48M · Q2 2026
More on Birchview Capital, LP
FAQ
How long has Birchview Capital, LP held PHVS?
Birchview Capital, LP has disclosed PHVS holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Birchview Capital, LP's current position in PHVS?
As of Q3 2026, Birchview Capital, LP holds 29.85K shares of PHVS (PHARVARIS N V), valued at $946.75K, representing 0.56% of its reported portfolio and ranking #40.
Has Birchview Capital, LP been buying or selling PHVS?
In the latest 13F filing (Q3 2026), Birchview Capital, LP held unchanged its position in PHVS. The position peaked in Q2 2026 at 29.85K shares.
Which other funds hold PHVS?
Other major institutional holders of PHVS include Foresite Capital Management IV, LLC, venBio Partners LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.